Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 20/20 | 0.76 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4591548 | 1.00 | CYP3A4 (0.76) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6923311 | 0.96 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1381723 | 0.96 | CYP3A4 (0.71) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4591485 | 0.94 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL4591449 | 0.94 | CYP3A4 (0.73) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1138350 | 0.88 | CYP3A4 (0.72) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL6923313 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1381726 | 0.87 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| Linaprazan SCHEMBL1138353 | 0.86 | CYP3A4 (1.00) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 | |
| SCHEMBL1138428 | 0.85 | CYP3A4 (0.68) | CYP3A4CYP2C9CYP2D6CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641793-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | claimed |
| EP-1879891-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECTIVE ACTIVITY | Nycomed GmbH (DE) | 2008-01-23 | — | — | EP | claimed |
| WO-2006117315-A1 | MUTUAL PRODRUG COMPOUNDS FOR USE AS ANTIINFLAMMATORY AGENTS WITH GASTROINTESTINAL PROTECCTIVE ACTIVITY | NYCOMED GMBH (DE) | 2006-11-09 | — | — | WO | claimed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| US-7691875-B2 | Imidazopyridine compounds, processes for their preparation and therapeutic uses thereof | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1641793-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| EP-1641793-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2008-02-13 | — | — | EP | disclosed |
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | ASTRAZENECA AB (SE) | 2007-03-22 | — | — | US | disclosed |
| EP-1641793-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | AstraZeneca AB (SE) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004113339-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND II WITH THERAPEUTIC EFFECT | ASTRAZENECA AB (SE) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066642-A1 | Novel imidazopyridine compound ii with therapeutic effect | GIPR, HRH2, VIP | CYP3A4 1521/4885CYP2C9 3408/4885CYP2D6 2510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.